Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 256

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study

West, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., Kuipers, E. J.·2004·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background : Ciprofloxacin is effective in perianal Crohn's disease but after treatment discontinuation symptoms reoccur. Infliximab is effective but requires maintenance therapy. Aim : To evaluate the effect of combined ciprofloxacin and infliximab in perianal Crohn's disease. Methods : A double‐blind placebo‐controlled study was conducted. Patients were randomly assigned to receive 500‐mg ciprofloxacin twice daily or a placebo for 12 weeks. All patients received 5‐mg/kg infliximab in week 6, 8 and 12 and were followed for 18 weeks. Primary end‐point was clinical response, defined as a 50% or greater reduction from baseline in the number of draining fistulae. Secondary end‐points were the change in Perianal Disease Activity Index and hydrogen peroxide enhanced three‐dimensional endoanal ultrasonography findings. Analysis was by intention‐to‐treat. Results : Twenty‐four patients were included but two discontinued treatment. At week 18, response was 73% (eight of 11) in the ciprofloxacin group and 39% (five of 13) in the placebo group (P = 0.12). Using logistic regression analysis patients treated with ciprofloxacin tended to respond better (OR = 2.37, CI: 0.94–5.98, P = 0.07). The Perianal Disease Activity Index score only improved (P = 0.008) in the ciprofloxacin group. Three‐dimensional endoanal ultrasonography improved in three patients with a clinical response. Conclusions : A combination of ciprofloxacin and infliximab tended to be more effective than infliximab alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02247.x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 256

Metadata

Authors
West, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., & Kuipers, E. J.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2004-12
Volume
20
Issue
11-12
Pages
1329-1336
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2063518063
Cited by
256
References
23
FWCI
4.38
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study. https://app.cochat.ai/papers/10.1111/j.1365-2036.2004.02247.x
The paper
West, R. L., van der Woude, C. J., Hansen, B. E., Felt‐Bersma, R. J. F., van Tilburg, A. J. P., Drapers, J. A. G., & Kuipers, E. J. (2004). Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double‐blind placebo‐controlled study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2004.02247.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.